Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant ruxolitinib with cytarabine-based chemotherapy in secondary AML from myeloproliferative neoplasm
KCT0003209Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in acute myeloid leukemia (AML), myeloproliferative disorder (MPD), sponsored by Novartis. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on KCT0003209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003209.